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Abstract
Caffeine is a well-established ergogenic aid, demonstrated to enhance performance across a wide range of capacities through 
a variety of mechanisms. As such, it is frequently used by both athletes and non-athletes alike. As a result, caffeine ingestion 
is ubiquitous in modern society, with athletes typically being exposed to regular non-supplemental caffeine through a variety 
of sources. Previously, it has been suggested that regular caffeine use may lead to habituation and subsequently a reduction 
in the expected ergogenic effects, thereby blunting caffeine’s performance-enhancing impact during critical training and 
performance events. In order to mitigate this expected performance loss, some practitioners recommended a pre-competition 
withdrawal period to restore the optimal performance benefits of caffeine supplementation. However, at present the evidence 
base exploring both caffeine habituation and withdrawal strategies in athletes is surprisingly small. Accordingly, despite the 
prevalence of caffeine use within athletic populations, formulating evidence-led guidelines is difficult. Here, we review the 
available research regarding habitual caffeine use in athletes and seek to derive rational interpretations of what is currently 
known—and what else we need to know—regarding habitual caffeine use in athletes, and how athletes and performance 
staff may pragmatically approach these important, complex, and yet under-explored phenomena.
Key Points: 
Regular caffeine use appears to reduce caffeine’s ergo-
genic effects.
However, this reduction can be offset by an increased 
caffeine dose.
There appears to be no advantage, and indeed some 
potential disadvantages, associated with short-term pre-
competition caffeine withdrawal.
1 Introduction
Caffeine (1,3,7-trimethylxanthine) is a widely used drug, 
consumed daily by 80% of the world’s population [1]. This 
large-scale consumption is driven by cultural and societal 
trends, along with the impact of both caffeine and coffee 
on short-term function and long-term health. As an illus-
tration, a number of meta-analyses have indicated the ben-
eficial effects of caffeine on a range of chronic conditions, 
including cardiovascular and metabolic disorders, cancers, 
neurological conditions, and overall mortality [2]. Caffeine 
also has an acute positive effect on alertness [3], fatigue 
reduction [4], concentration [5], and pain perception [6]. 
Consequently, caffeine is widely and frequently consumed, 
through coffee and other caffeinated mediums, for a variety 
of reasons, with an estimated UK adult mean daily caffeine 
intake of ~ 130 mg [7].
Additionally, caffeine enhances exercise performance 
[8], showing ergogenic effects on aerobic endurance [9], 
high-intensity efforts [10], muscular endurance [11, 12], 
sprint performance [13], and maximum strength [14]. As a 
result, it is frequently used by sportspeople, with research 
suggesting 75–90% of athletes consume caffeine before 
or during competitive events [15–17]. Although average 
figures are not available, athletes may consume greater 
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quantities of caffeine than their non-athletic peers due to 
the use of caffeinated sports supplements [18, 19]. Addition-
ally, within caffeine experiments, trained subjects typically 
self-report habitual daily consumptions greater than 300 mg 
[20–23], demonstrating increased caffeine intakes in these 
populations.
Caffeine intake has a long history of use as a perfor-
mance-enhancement strategy for competition, but more 
recently has attracted attention as a method to support train-
ing goals [24]. For example, athletes commonly use caffeine 
to offset fatigue associated with regular training [25, 26] and 
to mitigate sleep disruption caused by early morning training 
sessions [27] and jet lag [28]. Additionally, caffeine’s anal-
gesic qualities may mask soreness following high training 
or competition loads [29–31], thereby providing an addi-
tional avenue for performance enhancement. As such, whilst 
caffeine use in athletes and non-athletes is conventionally 
considered separately, evidently there is considerable over-
lap between the two. This is illustrated by research investi-
gating the optimal caffeine dose to enhance performance; 
historically, this relied on doses between 6 and 9 mg/kg, 
and sometimes as high as 13 mg/kg [32]. Such doses are dif-
ficult to attain without targeted supplementation. However, 
more recent research has shown caffeine can exert ergogenic 
effects at lower doses, including < 3 mg/kg [33]; such a dose 
is readily achieved through caffeine ingestion behaviors 
commonly seen in daily life.
Various sources contribute to the total caffeine load con-
sumed by athletes. The most popular is coffee, with 2.25 
billion cups consumed daily world-wide [34], along with 
other caffeinated beverages. Caffeine intake may also occur 
through the consumption of caffeine-containing foods, such 
as dark chocolate, and medications. Recently, the availability 
of caffeine-containing supplements, including tablets and 
energy drinks, has likely contributed to increased caffeine 
intakes in non-athletes and athletes [35]. The majority of 
these caffeine sources also include other compounds with 
potential positive effects, such as taurine in energy drinks 
(performance enhancement [36]), and both chlorogenic acid 
(health benefits [37]) and caffeic acid (promotion of post-
exercise glycogen synthesis [38]) in coffee.
Caffeine’s ubiquity raises the possibility that regular, 
repeated exposure may blunt the subsequent physiologi-
cal effects of supplementation. In animal studies, chronic 
caffeine intake increases adenosine receptor concentration 
[39, 40], attenuating caffeine’s stimulatory effects [41]. 
Chronic caffeine use also blunts some of the physiologi-
cal responses exhibited by caffeine-naïve individuals fol-
lowing acute caffeine ingestion, such as increased adrena-
line secretion [42]. However, caffeine habituation appears 
somewhat reversible following short-term cessation of caf-
feine consumption [43]. As such, if habitual caffeine use 
does blunt caffeine ergogenesis, this suggests short-term 
caffeine withdrawal may be advantageous to habitual caf-
feine users. At present, advice given to athletes regarding 
caffeine habituation and withdrawal is often vague and 
conflicting. The International Society of Sports Nutrition’s 
position stand summarizes research pertaining to caffeine 
habituation [44], but stops short of making recommenda-
tions. Contemporary sources further this confusion; some 
[45] state that habituation potentially harms performance, 
recommending pre-competition withdrawal. Others suggest 
habituation does not reduce caffeine’s ergogenic benefits, 
rendering pre-competition withdrawal unnecessary [46]. 
Consequently, athletes receive confusingly mixed messages, 
and best practice remains unclear.
The aim of this paper, therefore, is to reflect on two unre-
solved questions, both directly relevant to athletes seeking 
to optimize pre-competition caffeine use. First, we consider 
whether regular caffeine intake alters its ergogenic effects. 
Second, we explore whether, in habitual users, short-term 
pre-competition caffeine withdrawal restores caffeine’s ergo-
genic benefits. Both are critical considerations for athletes 
seeking to develop caffeine supplementation strategies to 
augment performance. Does regular caffeine intake alter 
caffeine’s ergogenic properties at the time when an athlete 
may need them most—during competition—or does caffeine 
habituation not impact performance?
2  Does Chronic Caffeine Use Alter Caffeine’s 
Acute Ergogenic Effects?
2.1  The Problem with Assessing Habitual Caffeine 
Use
Whilst tempting to believe the caffeine content of various 
caffeine sources is stable and consistent, there is consid-
erable variation in concentrations, both between different 
caffeine sources and within the same source across different 
time points [47, 48]. For example, the caffeine content of a 
single serving of espresso can vary from 25 to 214 mg across 
locations and by as much as 132 mg at the same location at 
different times [47]. Consequently, even when the same bev-
erage is consumed on a regular basis, daily caffeine intake 
likely varies considerably, making accurate determination 
of habitual caffeine intake problematic [49]. Within studies, 
food/beverage frequency questionnaires are often used to 
quantify habitual caffeine intake. However, given the con-
siderable variation between caffeine concentrations within 
the same source, these questionnaires likely do not accu-
rately capture true habitual caffeine intake. More objective 
measures of ingestion, such as urinary caffeine output [50] 
or plasma caffeine (or metabolite) levels [51], do exist, and 
could be used to more accurately quantify habitual caffeine 
intake alongside validated caffeine intake questionnaires, 
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although clearly such methods pose their own set of logis-
tical challenges. Such variation in caffeine concentrations 
across sources and time is also problematic for athletes try-
ing to accurately quantify desired caffeine doses.
Additionally, recent evidence suggests habitual caffeine 
use is influenced by individual responsiveness to its physi-
ological actions. For example, single-nucleotide polymor-
phisms (SNPs) in ADORA2A and CYP1A2 appear to impact 
habitual caffeine intake [52–54], with those possessing the 
more sensitive genotype consuming less caffeine. Such find-
ings further complicate our understanding of the effects of 
habitual caffeine use in athletes; given the individual respon-
siveness to caffeine, is habitual use a function of specific 
genetic polymorphisms, making measurement of habitual 
caffeine intake a proxy for genotype? Furthermore, these 
SNPs may also impact caffeine’s ergogenic effects, with 
C allele carriers of CYP1A2 (rs762551) tending to exhibit 
smaller performance benefits [55, 56], potentially demon-
strating an ergolytic effect [57]. In a pilot study exploring 
the impact of ADORA2A on caffeine ergogenesis, the TT 
genotype was associated with greater performance enhance-
ment following caffeine ingestion prior to a cycle ergom-
eter time trial [58]. A potential confounder here, however, 
is that CT/TT genotypes also tended to habitually consume 
more caffeine than TT genotypes (although this was not sig-
nificant), and may subsequently have become habituated. 
Furthermore, the small sample size (n = 12) also severely 
limits the interpretations possible. These findings further 
complicate the analysis of the impact of habitual caffeine use 
on athletes; are we measuring the impact of habitual caffeine 
use on performance, or are we measuring the interaction of 
caffeine and genotype—which is rarely determined in inves-
tigative studies—on performance?
2.2  Habitual Caffeine Use and Athletic Performance
Habitual caffeine intake modifies physiological and cog-
nitive responses to acute caffeine doses [41, 42, 59]. The 
underpinning mechanisms are varied, and remain incom-
pletely understood. The majority of research in this field 
utilizes animal models. Here, the dose of caffeine used is 
often very large (such as 80 mg/kg) [60], and often given as 
a single bolus, as opposed to the lower, more regular doses 
typical of human ingestion patterns, making direct compari-
sons difficult. Nevertheless, perhaps the best supported path-
way of caffeine habituation is the alteration of physiological 
responses caused by the up-regulation of adenosine receptors 
[59]. Additionally, regular exposure to substrates that induce 
cytochrome P450 1A2—a key part of the caffeine metaboli-
zation pathway [61, 62] —appears to increase the induction 
speed of that enzyme [63, 64]. As such, habitual caffeine 
use may alter caffeine metabolization speed. The time frame 
of such changes is poorly understood, although withdrawal 
symptoms, suggesting habituation, can occur after only 
3 days of caffeine consumption [65]. For athletes, the key 
consideration is whether this impacts sporting performance. 
Van Soeren et al. [66] examined the impact of caffeine on 
physiological responses in habitual users and non-users in 
an exercise setting, focusing on alterations in plasma epi-
nephrine, plasma and urinary caffeine concentrations, free 
fatty acid concentrations, and respiratory exchange ratio, as 
opposed to specific performance tests. Whilst there were 
apparent differences between the groups in some of these 
variables, in the absence of performance tests, it is impos-
sible to determine whether these differences resulted in any 
real-world performance detriments. Similarly, other studies 
also used subject pools comprising habitual users and non-
users, but again did not analyze differences in performance 
between them [67, 68].
The first study utilizing a performance test [20] recruited 
17 moderately trained males, of whom eight were non-
habitual (< 25 mg/day) and nine habitual caffeine users 
(> 300 mg/day) (Table 1). All subjects undertook time-to-
exhaustion trials under three experimental conditions: pla-
cebo, 3 mg/kg caffeine, and 5 mg/kg caffeine. There were no 
differences between the groups regarding time to exhaustion 
at either dose, indicating habitual caffeine use does not blunt 
caffeine’s ergogenic effects. In contrast, Bell and McLellan 
[22] recruited 13 habitual users (≥ 300 mg/day) and eight 
non-users (< 50 mg/day) to undertake cycle ergometer time-
to-exhaustion tests following ingestion of 5 mg/kg caffeine 
either 1, 3, or 6 h prior. Subsequent results suggested the 
magnitude and duration of ergogenic effects were greater 
in the non-users than the habitual users. When caffeine was 
consumed both 1 and 3 h pre-test, the habitual caffeine users 
exhibited an ergogenic effect following caffeine ingestion, 
but this was smaller than that exhibited by the non-users—
indicating a blunting, but not loss of, caffeine ergogenicity 
with habitual use.
More recently, 18 habitually low (< 75 mg/day) caffeine 
users were randomly assigned to receive either daily caffeine 
supplementation (starting at 1.5 mg/kg and increasing to 
3 mg/kg) or placebo for 28 days [69]. Following this sus-
tained supplementation period, all subjects ingested 3 mg/
kg caffeine 60 min prior to a 60-min cycle at 60% of peak 
oxygen consumption (VO2peak), immediately followed by a 
30-min maximum cycle. When compared to their pre-inter-
vention, caffeine-supplemented exercise trial, there was a 
7.3% reduction in total work produced by habituated caffeine 
users, representing a probably harmful effect of habitual caf-
feine use based on magnitude-based inferences. However, 
the ergogenic effect was not completely diminished; com-
pared to the pre-intervention placebo trial, caffeine supple-
mentation still exhibited a possibly beneficial effect follow-
ing acute caffeine ingestion. In contrast, the chronic placebo 
supplementation group exhibited no differences between the 
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pre- and post-intervention caffeine trials, again suggesting 
that regular caffeine use reduces, but does not eliminate, 
caffeine’s ergogenic effects.
Finally, Gonçalves and colleagues [23] stratified 40 
male endurance-trained cyclists into groups based on their 
habitual caffeine intake: low (mean = 58 mg/day), moder-
ate (mean = 143 mg/day), and high (mean = 351 mg/day). 
These subjects underwent a simulated cycling time trial of 
approximately 30 min duration under three conditions: a caf-
feine trial with 6 mg/kg, a placebo trial, and a control trial. 
Habitual caffeine intake exerted no influence on exercise 
performance, suggesting caffeine habituation had no detri-
mental impact on caffeine ergogenesis.
2.3  What to Make of These Results?
Gonçalves et al. [23] titled their paper “Dispelling the myth 
that habitual caffeine consumption influences the perfor-
mance response to acute caffeine supplementation.” Whilst 
this title certainly reflects their study results, it is perhaps 
premature given the results of Bell and McLellan [22] 
and Beaumont et al. [69]. Dispelling “the myth” requires 
more than a single contradictory finding, especially given 
recent findings regarding differences in ergogenic effects 
in habitual and non-habitual caffeine users following low-
dose caffeine-gum supplementation [70]. In evaluating this 
claim, it is worth inspecting the differences in study designs. 
The major distinction lies in the different habitual and pre-
trial caffeine doses employed. Beaumont et al. [69] utilized 
habitual and pre-trial caffeine doses of 3 mg/kg, such that 
the pre-trial and habitual caffeine doses were identical. Bell 
and McLellan [22] utilized a pre-trial dose of 5 mg/kg. The 
subjects in the habitual caffeine group had habitual intakes 
of at least 300 mg/day, equating to approximately 4 mg/kg/
day. In this case, the pre-trial caffeine dose was close to, but 
slightly greater than, the habitual caffeine dose. In contrast, 
in Gonçalves et al.’s study [23], habitual caffeine intake in 
the high group was 351 mg/day, equating to ~ 4.5 mg/kg/day, 
somewhat lower than the pre-trial dose of 6 mg/kg. Dodd 
et al. [20] did not provide body mass data, so we were unable 
to analyze differences between habitual and pre-trial caffeine 
dose; however, with a mean caffeine intake of 495 mg/day 
in the habitual group, it is unlikely that the pre-trial dose of 
5 mg/kg was substantially greater than this.
The studies are also heterogeneous in other aspects. The 
exercise trials were a mix of time-to-exhaustion [20, 22] 
and time trials [23], consequently impacting the ability to 
directly compare trials [71]. Whilst all studies recruited 
males, Bell and McLellan [22] also recruited females, 
who may metabolize caffeine differently to males [72, 73], 
although it is not clear whether this impacts caffeine ergo-
genesis [74, 75]. Additionally, training status varied between 
studies, with competitive cyclists [23] and recreationally Ta
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active subjects [69] recruited. Again, training status poten-
tially alters the ergogenic effects of caffeine [76, 77]. Fur-
thermore, differences in pre-trial fasting (e.g., overnight [69] 
vs 4 h [20]) may have impacted both energy status and caf-
feine ergogenicity. Finally, as previously discussed, habitual 
caffeine intake was assessed via food frequency question-
naires, which are subject to recall bias [78], further hamper-
ing thorough interpretation.
In summary, it appears that habitual caffeine use may 
reduce the magnitude of caffeine’s ergogenic effects; how-
ever, any reductions in caffeine ergogenicity with habitual 
use are potentially modified by pre-trial doses substantially 
greater than habitual intake. At present, these conclusions 
are based on little evidence, and further research is certainly 
required.
2.4  What Does This Mean for Athletes?
If caffeine-habituated individuals require greater caffeine 
doses to maintain ergogenic effects, this is potentially prob-
lematic for athletes. Evidence suggests there are no addi-
tional ergogenic effects of caffeine above doses of 9 mg/kg 
[32, 79]; if athletes habitually consume moderate-to-high 
doses of caffeine (~ 4–5 mg/kg), there may be a point at 
which further caffeine ingestion does not restore caffeine’s 
full ergogenic potential. Whilst such habitual intakes appear 
extreme, the regular intake of subjects in some research stud-
ies [80] reaches this level. Additionally, higher doses of caf-
feine may increase the risk of reported side effects, such as 
tremor, insomnia, and increased heart rate [32, 79, 81].
Furthermore, as caffeine’s ergogenic effects occur 
through a variety of mechanisms, the time course and 
magnitude of habituation likely vary for each molecular 
pathway. For example, caffeine is primarily metabolized 
by cytochrome P450 enzymes [62]. Regular caffeine con-
sumption upregulates production of this enzyme group [82], 
increasing metabolization speed in habitual users. Thus, 
variation in cytochrome P450 activity, which is partially 
genetically determined [61], may impact caffeine ergogen-
esis [55–57]. This increased caffeine metabolization rate in 
habitual users is likely a major reason why regular use may 
require larger dosages to exert an effect previously experi-
enced at lower dosages, with greater amounts of caffeine 
required to maintain the concentration driving the ergogenic 
effects. Aside from metabolization speed, habituation may 
also occur through changes in adenosine receptor density 
[41], which again is subject to inter-individual variability 
mediated through genetic variation [58]. The time course of 
habituation is poorly understood, potentially differs between 
pathways, and is likely affected by factors such as habitual 
dose [60]. For example, in rats, complete caffeine tolerance 
occurs following a dose of 40 mg/kg spread over the pre-
ceding 24 h [83], whilst a lower dose (7.5 mg/kg) requires 
14 days to achieve habituation [41]. Additionally, the time 
course for habituation within each individual pathway may 
also differ between individuals, adding further complexity 
to our attempts to understand the effects of caffeine habitu-
ation in athletes.
3  Does Caffeine Withdrawal in Habitual 
Users Restore Optimized Ergogenic 
Effects?
If habitual caffeine use requires an increased pre-competi-
tion dose to restore the ergogenic effects, and this increase 
enlarges the risk of negative side effects, an alternative 
option may be for the athlete to cease caffeine use for a short 
period beforehand. This method has previously been pro-
posed as a way to become re-sensitized to caffeine’s physi-
ological effects [80], potentially mediated through changes 
in adenosine receptors [84] or by overcoming compensatory 
changes in the dopaminergic system due to chronic and con-
sistent blockage of adenosine receptors with high caffeine 
use [85]. The time course of re-sensitization remains unclear, 
and is potentially impacted by both the duration and extent 
of prior caffeine exposures [65]. Similar to caffeine habitua-
tion studies, many studies exploring caffeine withdrawal are 
conducted in rodents, utilizing what would be, for humans, 
unrealistically large caffeine dosages (e.g., 194 mg/kg/day) 
[84]. Finally, it remains unclear whether caffeine withdrawal 
actually re-sensitizes subjects to the physiological effects of 
caffeine, or whether the reintroduction of caffeine following 
a period of abstinence merely reverses the many side effects 
associated with withdrawal [86–88]. Again, despite its rel-
evance, only a few studies have investigated the potential 
association between temporary caffeine withdrawal and the 
restoration of caffeine’s ergogenic effects.
An early study [80] examined the influence of 4 days’ 
caffeine withdrawal on the ergogenic effects of 5 mg/kg 
of caffeine in six habitual (> 600 mg/day) caffeine users 
(Table 2). Whilst the withdrawal period increased the sensi-
tivity of some individuals to caffeine in terms of physiologi-
cal responses, physical performance itself was not measured. 
Subsequently, Van Soeren and Graham [21] put six habitual 
caffeine users (mean daily caffeine intake 761 mg/day) 
through time-to-exhaustion cycling trials with 0-, 2-, and 
4-day caffeine withdrawal periods prior to a pre-trial caffeine 
dose of 6 mg/kg. Although time to exhaustion was longer in 
all caffeine trials compared to placebo, no significant differ-
ences existed between withdrawal periods.
More recently [89] 12 well-trained male cyclists with an 
average habitual caffeine intake of 240 mg/day abstained 
from caffeine for 4 days, during which they received daily 
supplementation with either placebo or 1.5 mg/kg caffeine. 
On the fifth day, the subjects consumed 3 mg/kg caffeine 
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90 min prior to a cycle time trial. Pre-trial caffeine inges-
tion significantly enhanced time-trial performance in both 
conditions (habitual placebo and caffeine), with no sig-
nificant differences between the two. Consequently, the 
authors concluded the 4-day withdrawal period did not 
enhance caffeine ergogenicity. As with habituation, stud-
ies exploring caffeine withdrawal are heterogeneous, with 
differences in subject sex, habitual caffeine intakes, and 
exercise modalities. Additionally, the findings from Fisher 
et al. [80] and Van Soeren and Graham [21] may have been 
affected by very high habitual intakes, which were over 
four times the average population daily intake [7] and dou-
ble the doses commonly seen in habitual users in caffeine 
studies [20]; as such, it is difficult to extrapolate these 
results into the context of caffeine utilization in athletes.
In summary, it appears short-term, pre-competition caf-
feine withdrawal in habitual users does not enhance caf-
feine’s ergogenic effects. Withdrawal is also associated 
with numerous negative outcomes, including headaches, 
fatigue [21], irritability, muscle pain, sleep disturbances, 
and nausea [85, 87]. Fortunately, such symptoms appear 
limited to a sub-set of individuals, are typically mild and 
temporary [24], and reverse with caffeine ingestion [88]. 
Nevertheless, such acute withdrawal symptoms, close to 
key competitions, may negatively affect athlete subjective 
confidence and well-being.
4  Rational Interpretations and Practical 
Implications
The summarized research (Tables 1 and 2) suggests:
• Habituation, in terms of reduced ergogenic effects, may 
occur in those who regularly consume caffeine [69].
• Habituation can result in reduced caffeine ergogenesis, 
but this may be offset if the pre-competition caffeine 
dose is greater than the habitual dose [23].
• Short-term caffeine withdrawal prior to key events 
appears to offer little or no competitive benefit to habit-
ual users [89].
With caffeine shown to exert its greatest ergogenic effects 
at between 3 and 9 mg/kg, there is a wide range of dosages 
for athletes to consume around competition. Previously, we 
discussed the considerable inter-individual variation under-
pinning both caffeine ergogenicity and the dose necessary to 
achieve performance benefits [90]. Such variation is a prod-
uct of complex interactions between genetics, environmental 
exposures, and epigenetic modifications. Accordingly, any 
one-size-fits-all recommendations regarding caffeine use 
appear fundamentally flawed, and should be avoided. Some 
individuals may find the peak ergogenic effects of caffeine 
occur towards the lower end of this 3- to 9-mg/kg window; 
here, it may be prudent to habitually consume lower caf-
feine doses, as the scope for consuming the required caffeine 
dose to offset habituation is smaller. Conversely, individuals 
exhibiting peak ergogenic benefits at higher doses may toler-
ate greater habitual intakes, as there is an increased scope 
for consumption of greater pre-competition caffeine doses. 
A further consideration is that of the negative side effects 
of caffeine use, which tend to be most pronounced in non-
habitual users [32, 79, 81]. In this case, if the athlete wishes 
to explore the potential ergogenic benefits of caffeine, then 
initiating habitual use may be beneficial in order to reduce 
the prevalence or intensity of any negative side effects.
4.1  Inter‑individual Variation in Caffeine 
Habituation and Performance
Considerable variation exists in caffeine responsiveness 
between individuals [90]. This inter-individual variation is 
partially genetically determined, with SNPs in genes such as 
ADORA2A and CYP1A2 influencing both habitual caffeine 
use [52, 53] and caffeine ergogenicity [55–58]. As such, fur-
ther insights into the genetic differences between subjects 
may allow for a greater individualization of pre-competition 
caffeine advice [90]. Adding to this complexity, there is 
likely inter-individual variation in the time-course, magni-
tude, and mechanisms of caffeine habitation. For example, 
caffeine’s ergogenic effects are mediated via multiple pro-
posed pathways, such as altering fat metabolism [91, 92], or 
reducing perceived exercise-associated pain [93]. Genetic 
variations within these pathways, coupled with individual 
Table 2  Characteristics and findings of studies directly examining the effects of caffeine withdrawal on exercise performance
Study Subjects Habitual dose Washout period Pre-trial dose Outcome
Fisher et al. [80] 6 habitual users > 600 mg/day 4 days 5 mg/kg No direct performance measure
Van Soeren and 
Graham [21]
6 habitual users Mean of 761 mg/day 0, 2, and 4 days 6 mg/kg No significant differences in time-trial perfor-
mance between washout periods
Irwin et al. [89] 12 well-trained 
male cyclists
Mean of 240 mg/day 
(range 18–469 mg/
day)
4 days (placebo 
or 1.5 mg/kg)
3 mg/kg No difference between placebo and caffeine group
Caffeine Habituation and Performance
history, may modify the effectiveness of each pathway, alter-
ing the performance of individuals to differing extents. Sub-
sequently, for example, during a marathon, athlete A may 
gain a greater performance benefit from caffeine’s impact on 
fat metabolism, whilst athlete B gains their ergogenic effect 
from a reduction in pain. Does habitual caffeine use alter 
both these phenotypes to the same extent? Does regular caf-
feine exposure modify fat metabolism to a greater or lesser 
extent than pain reduction? Can the diminished ergogenic 
effect be offset through other ergogenic aids, such as paracet-
amol in the case of pain reduction [94]? Does habituation 
occur sooner in one pathway than another? Do the multiple 
ergogenic benefits of caffeine manifest in all consumers or is 
every individual specifically sensitive to some while resist-
ant to others? The answers to these questions are undoubt-
edly complex, and we may never know the answers—illus-
trating how wary we should be of one-size-fits-all advice.
4.2  Some Tentative Recommendations
Given the current lack of adequate research and the inevita-
bility of inter-individual variations in response to caffeine, 
any advice at this stage is somewhat speculative. Addition-
ally, a wide-ranging assessment of caffeine recommenda-
tions is beyond the scope of this review; however, based on 
the limited research available, when considering caffeine 
habituation and pre-competition exercise withdrawal, it 
seems sensible to suggest the following:
1. As caffeine is widely consumed, with a number of social 
and health benefits outside of performance enhance-
ment, a pragmatic approach is to understand that the 
majority of athletes will consume caffeine outside of 
deliberate pre-competition ingestion. Based on the evi-
dence presented here, it appears moderate (~ 3 mg/kg) 
daily doses of caffeine will not be problematic for most 
athletes, most of the time.
2. As caffeine has a multitude of positive effects on train-
ing performance, it can—and perhaps should—be used 
either prior to or during training. For most sport types, 
if used prior to training, we would recommend consum-
ing caffeine approximately 60 min prior to the onset of 
the first working set of the session. This time scale will 
differ between individuals [95], event types [44], and 
methods of caffeine ingestion, with caffeinated mouth 
rinses and gums often requiring far less time [96]. If 
used during prolonged training sessions, there is evi-
dence that later ingestion of caffeine, and at lower doses, 
may be effective [97].
3. For most athletes, the total of regular caffeine intake 
spread across the day, including the pre- and intra-
training dose, should not exceed 3 mg/kg, as this will 
increase the required pre-competition caffeine dose sub-
stantially. Ingesting caffeine later within a training ses-
sion often requires a lower dose [97], which may further 
guard against habituation.
4. Given the individual response to caffeine, both in terms 
of habituation and ergogenesis, athletes should experi-
ment with various doses and timing strategies when 
using caffeine to enhance performance [90, 95]. As a 
broad start point, we recommend athletes who are not 
caffeine naïve, but also not high habitual users, utilize 
approximately 3 mg/kg approximately 60 min prior to a 
competitive bout, and then adjust accordingly. Alterna-
tively, athletes may wish to estimate their daily caffeine 
intake (whilst understanding the methodological issues 
in doing so), and double this dose to obtain an idea of 
their pre-competition dose. For athletes competing in 
prolonged events, caffeine may need to be consumed 
closer to, or indeed within, the competitive bout in order 
to enhance performance.
5. There appears to be no benefit from, and potentially 
negative consequences of, a short-term, pre-competi-
tion caffeine withdrawal period. The impact of longer 
(> 7-day) withdrawal periods has not, to our knowledge, 
been explored in the context of performance.
6. The impact of pre-competition caffeine doses on a sub-
sequent performance bout in a short time frame (such as 
in heats and finals of a track event separated by ~ 90 min) 
is currently poorly explored [98]. Again, a pragmatic 
approach is perhaps required; if the athlete requires the 
performance benefits of caffeine to progress through the 
first event, then caffeine should be consumed at that time 
point. Athletes may then experiment with the optimal 
“top-up” dose to be consumed between heats and final.
Future research should seek to confirm whether habitu-
ation systematically reduces caffeine’s ergogenic effects 
(as per Beaumont et al. [69]), confirm whether increased 
caffeine dosages can offset this reduction (as per our 
analysis of Gonçalves et al. [23]), and elucidate the driv-
ers of the inter-individual response to each. In addition, 
investigating the impact of longer term (> 7-day) caffeine 
withdrawal periods, to see if this enhances the ergogenic 
effect of a subsequent caffeine dose, seems advisable. Such 
an approach may prove useful to those competing infre-
quently, such as in a marathon, as opposed to those com-
peting on a more regular basis, where constant exposure to 
caffeine would be expected. Finally, the impact of caffeine 
ingestion on sequential competitive bouts performed in a 
short time frame remains, from the athlete’s perspective, 
highly relevant, and yet is poorly explored [96]. Further 
exploration of this would likely be of great practical use 
to athletes.
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5  Conclusions
In summary, caffeine habituation may blunt the expected 
ergogenic effects, although this may be mitigated by 
increasing pre-competition caffeine dose. Furthermore, 
short-term pre-competition caffeine withdrawal appears 
to offer little benefit, and given the potential negative side-
effects, such practices are not recommended. Currently, it 
appears that moderate (~ 3 mg/kg/day) chronic caffeine 
intake is not problematic for most athletes. However, there 
is likely to be substantial inter-individual variation [95], 
both in regard to optimal caffeine dose and timing and 
also the effects of habituation and withdrawal. As such, 
we should be wary of a one-size-fits-all approach. In the 
absence of well-replicated research in this area, a prag-
matic approach is recommended for athletes. Here, the 
currently available research provides athletes and practi-
tioners with an informed starting point, from which they 
can then experiment with different caffeine strategies—
both acute and chronic—during training periods in order 
to enhance caffeine’s ergogenic effects within competi-
tion. Once an effective strategy is found, it can be refined 
and rehearsed, optimizing performance. As illustrated, the 
relationship between caffeine, habitual use, and perfor-
mance is complex and nuanced, poorly understood, and 
ever-changing within the individual. Nevertheless, conven-
tionally, we persist in recycling and utilizing generalized 
guidelines to inform caffeine ingestion strategies. We can, 
and should, improve this process.
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